HRP20210544T1 - Inhibitori farneziltransferaze za uporabu u liječenju raka - Google Patents
Inhibitori farneziltransferaze za uporabu u liječenju raka Download PDFInfo
- Publication number
- HRP20210544T1 HRP20210544T1 HRP20210544TT HRP20210544T HRP20210544T1 HR P20210544 T1 HRP20210544 T1 HR P20210544T1 HR P20210544T T HRP20210544T T HR P20210544TT HR P20210544 T HRP20210544 T HR P20210544T HR P20210544 T1 HRP20210544 T1 HR P20210544T1
- Authority
- HR
- Croatia
- Prior art keywords
- tipifarnib
- scchn
- ras
- use according
- mutation
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title 1
- 239000003528 protein farnesyltransferase inhibitor Substances 0.000 title 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N tipifarnib Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 claims 14
- 229950009158 tipifarnib Drugs 0.000 claims 14
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims 13
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims 13
- 230000035772 mutation Effects 0.000 claims 11
- 210000004072 lung Anatomy 0.000 claims 8
- 102100029974 GTPase HRas Human genes 0.000 claims 5
- 101710113436 GTPase KRas Proteins 0.000 claims 5
- 102100039788 GTPase NRas Human genes 0.000 claims 5
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 claims 5
- 101000744505 Homo sapiens GTPase NRas Proteins 0.000 claims 5
- 241000701806 Human papillomavirus Species 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 229960005395 cetuximab Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 108020004705 Codon Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 210000002050 maxilla Anatomy 0.000 claims 1
- 230000001394 metastastic effect Effects 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- 210000000214 mouth Anatomy 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 210000003437 trachea Anatomy 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2531/00—Reactions of nucleic acids characterised by
- C12Q2531/10—Reactions of nucleic acids characterised by the purpose being amplify/increase the copy number of target nucleic acid
- C12Q2531/113—PCR
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Claims (13)
1. Tipifarnib za uporabu u postupku liječenja karcinoma pločastih stanica glave i vrata (SCCHN) otpornog na cetuksimab kod subjekta, naznačen time što SCCHN ima mutaciju HRAS.
2. Tipifarnib za uporabu u postupku liječenja karcinoma pločastih stanica pluća (SCC pluća) otpornog na cetuksimab kod subjekta, naznačen time što SCC pluća ima mutaciju HRAS.
3. Tipifarnib za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni SCCHN ili navedeni SCC pluća nemaju mutaciju K-Ras ili mutaciju N-Ras.
4. Tipifarnib za uporabu u skladu s patentnim zahtjevom 3, naznačen time što navedeni SCCHN ili navedeni SCC pluća imaju divlji tip K-Ras i divlji tip N-Ras.
5. Tipifarnib za uporabu u skladu s patentnim zahtjevom 1 ili 2, naznačen time što postupak sadrži:
(a) utvrđivanje prisutnosti ili odsutnosti mutacije HRAS u uzorku od navedenog subjekta, i naknadno
(b) davanje terapijski učinkovite količine navedenog tipifarniba navedenom subjektu ako se utvrdi da navedeni uzorak ima mutaciju HRAS.
6. Tipifarnib za uporabu u skladu s patentnim zahtjevom 5, naznačen time što postupak nadalje obuhvaća utvrđivanje prisutnosti ili odsutnosti mutacije K-Ras ili mutacije N-Ras; i
pri čemu je utvrđeno da navedeni uzorak nema mutaciju K-Ras ili mutaciju N-Ras.
7. Tipifarnib za uporabu u skladu s patentnim zahtjevom 6, naznačen time što je utvrđeno da navedeni uzorak ima divlji tip K-Ras i divlji tip N-Ras.
8. Tipifarnib za uporabu u skladu s bilo kojim od patentnih zahtjeva 5 do 7, naznačen time što je navedeni uzorak biopsija tkiva ili biopsija tumora.
9. Tipifarnib za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je navedeni SCCHN ili navedeni SCC pluća negativan na HPV (humani papiloma virus).
10. Tipifarnib za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što je navedeni SCCHN ili navedeni SCC pluća u poodmakloj fazi ili je metastatski.
11. Tipifarnib za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 10, naznačen time što je navedeni SCCHN relapsni SCCHN ili je navedeni SCC pluća relapsni SCC pluća.
12. Tipifarnib za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što navedeni SCCHN je SCCHN dušnika, SCCHN maksile, ili SCCHN usne šupljine.
13. Tipifarnib za uporabu u skladu s bilo kojim od patentnih zahtjeva 1 do 12, naznačen time što navedena mutacija HRAS obuhvaća zamjenu aminokiselina na kodonu odabranom iz skupine koja se sastoji od G12, G13, Q61, Q22, K117, A146, i bilo koje njihove kombinacije.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662417044P | 2016-11-03 | 2016-11-03 | |
PCT/US2017/059686 WO2018085518A2 (en) | 2016-11-03 | 2017-11-02 | Methods of treating cancer patients with farnesyltransferase inhibitors |
EP17842428.9A EP3534885B1 (en) | 2016-11-03 | 2017-11-02 | Farnesyltransferase inhibitors for use in treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20210544T1 true HRP20210544T1 (hr) | 2021-08-20 |
Family
ID=61249690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20210544TT HRP20210544T1 (hr) | 2016-11-03 | 2021-04-06 | Inhibitori farneziltransferaze za uporabu u liječenju raka |
Country Status (26)
Country | Link |
---|---|
US (2) | US11124839B2 (hr) |
EP (2) | EP3838275A1 (hr) |
JP (1) | JP2019534290A (hr) |
KR (1) | KR20190082247A (hr) |
CN (1) | CN110325212B (hr) |
AR (1) | AR110031A1 (hr) |
AU (1) | AU2017353838A1 (hr) |
BR (1) | BR112019009000A2 (hr) |
CA (1) | CA3042747A1 (hr) |
DK (1) | DK3534885T3 (hr) |
EA (1) | EA201991091A1 (hr) |
ES (1) | ES2863730T3 (hr) |
HR (1) | HRP20210544T1 (hr) |
HU (1) | HUE053927T2 (hr) |
IL (1) | IL266182A (hr) |
LT (1) | LT3534885T (hr) |
MX (1) | MX2019005065A (hr) |
MY (1) | MY190861A (hr) |
PH (1) | PH12019500927A1 (hr) |
PL (1) | PL3534885T3 (hr) |
PT (1) | PT3534885T (hr) |
RS (1) | RS61745B1 (hr) |
SG (1) | SG11201903786UA (hr) |
SI (1) | SI3534885T1 (hr) |
TW (1) | TW201818965A (hr) |
WO (1) | WO2018085518A2 (hr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3277842T (pt) | 2015-08-17 | 2019-09-05 | Kura Oncology Inc | Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase |
EP3838275A1 (en) | 2016-11-03 | 2021-06-23 | Kura Oncology, Inc. | Farnesyltransferase inhibitors for use in methods of treating cancer |
TW202016316A (zh) * | 2018-06-19 | 2020-05-01 | 日商武田藥品工業股份有限公司 | 癌症治療方法 |
WO2020092720A2 (en) * | 2018-11-01 | 2020-05-07 | Kura Oncology, Inc. | Methods of treating cancer with farnesyltransferase inhibitors |
AU2019403379A1 (en) * | 2018-12-21 | 2021-07-15 | Kura Oncology, Inc. | Therapies for squamous cell carcinomas |
CA3134825A1 (en) * | 2019-03-29 | 2020-10-08 | Kura Oncology, Inc. | Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors |
JP2023500906A (ja) * | 2019-11-08 | 2023-01-11 | インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル) | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
Family Cites Families (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US4018653A (en) | 1971-10-29 | 1977-04-19 | U.S. Packaging Corporation | Instrument for the detection of Neisseria gonorrhoeae without culture |
US4044126A (en) | 1972-04-20 | 1977-08-23 | Allen & Hanburys Limited | Steroidal aerosol compositions and process for the preparation thereof |
GB1429184A (en) | 1972-04-20 | 1976-03-24 | Allen & Hanburys Ltd | Physically anti-inflammatory steroids for use in aerosols |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4016043A (en) | 1975-09-04 | 1977-04-05 | Akzona Incorporated | Enzymatic immunological method for the determination of antigens and antibodies |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
US4424279A (en) | 1982-08-12 | 1984-01-03 | Quidel | Rapid plunger immunoassay method and apparatus |
KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
US5310652A (en) | 1986-08-22 | 1994-05-10 | Hoffman-La Roche Inc. | Reverse transcription with thermostable DNA polymerase-high temperature reverse transcription |
US5561058A (en) | 1986-08-22 | 1996-10-01 | Hoffmann-La Roche Inc. | Methods for coupled high temperatures reverse transcription and polymerase chain reactions |
US5693517A (en) | 1987-06-17 | 1997-12-02 | Roche Molecular Systems, Inc. | Reagents and methods for coupled high temperature reverse transcription and polymerase chain reactions |
US5322770A (en) | 1989-12-22 | 1994-06-21 | Hoffman-Laroche Inc. | Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription |
WO1989001050A1 (en) | 1987-07-31 | 1989-02-09 | The Board Of Trustees Of The Leland Stanford Junior University | Selective amplification of target polynucleotide sequences |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
CA1340807C (en) | 1988-02-24 | 1999-11-02 | Lawrence T. Malek | Nucleic acid amplification process |
US4870287A (en) | 1988-03-03 | 1989-09-26 | Loma Linda University Medical Center | Multi-station proton beam therapy system |
US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
CA2020958C (en) | 1989-07-11 | 2005-01-11 | Daniel L. Kacian | Nucleic acid sequence amplification methods |
US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
US5976851A (en) | 1990-04-18 | 1999-11-02 | Board Of Regents, The University Of Texas System | Methods and compositions for the identification, characterization, and inhibition of farnesyl protein transferase |
US5420245A (en) | 1990-04-18 | 1995-05-30 | Board Of Regents, The University Of Texas | Tetrapeptide-based inhibitors of farnesyl transferase |
US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
US5210015A (en) | 1990-08-06 | 1993-05-11 | Hoffman-La Roche Inc. | Homogeneous assay system using the nuclease activity of a nucleic acid polymerase |
IL100040A (en) | 1990-11-13 | 1995-12-31 | Siska Diagnostics Inc | Amplification of nucleic acids by replicating a self-sustaining enzymatic sequence |
US5455166A (en) | 1991-01-31 | 1995-10-03 | Becton, Dickinson And Company | Strand displacement amplification |
US5238922A (en) | 1991-09-30 | 1993-08-24 | Merck & Co., Inc. | Inhibitors of farnesyl protein transferase |
US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
ATE205542T1 (de) | 1992-03-04 | 2001-09-15 | Univ California | Vergleichende genomhybridisierung |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US5686472A (en) | 1992-10-29 | 1997-11-11 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5504212A (en) | 1992-10-29 | 1996-04-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
EP0763537A3 (en) | 1993-05-14 | 1997-10-22 | Genentech Inc | Non-peptides farnesyl transfer inhibitors |
US5602098A (en) | 1993-05-18 | 1997-02-11 | University Of Pittsburgh | Inhibition of farnesyltransferase |
US5965539A (en) | 1993-05-18 | 1999-10-12 | Univeristy Of Pittsburgh | Inhibitors of prenyl transferases |
US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US5721236A (en) | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5523430A (en) | 1994-04-14 | 1996-06-04 | Bristol-Myers Squibb Company | Protein farnesyl transferase inhibitors |
FR2721021B1 (fr) | 1994-06-10 | 1996-07-12 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnésyl transférase, leur préparation et les compositions pharmaceutique qui les contiennent. |
IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
US5491063A (en) | 1994-09-01 | 1996-02-13 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
US5661161A (en) | 1994-09-29 | 1997-08-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5491164A (en) | 1994-09-29 | 1996-02-13 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5585359A (en) | 1994-09-29 | 1996-12-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5571673A (en) | 1994-11-23 | 1996-11-05 | Hoffmann-La Roche Inc. | Methods for in-solution quenching of fluorescently labeled oligonucleotide probes |
FR2729390A1 (fr) | 1995-01-18 | 1996-07-19 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2730491B1 (fr) | 1995-02-09 | 1997-03-14 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
US5700806A (en) | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5684013A (en) | 1995-03-24 | 1997-11-04 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5534537A (en) | 1995-03-29 | 1996-07-09 | Merck & Co., Inc. | Prodrugs of inhibitors of farnesyl-protein transferase |
US5578629A (en) | 1995-03-29 | 1996-11-26 | Merck & Co., Inc. | Benzamide-containing inhibitors of farnesyl-protein transferase |
US5972984A (en) | 1995-06-06 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5756528A (en) | 1995-06-06 | 1998-05-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
EP0835101B1 (en) | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
FR2736641B1 (fr) | 1995-07-10 | 1997-08-22 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
FR2736638B1 (fr) | 1995-07-12 | 1997-08-22 | Rhone Poulenc Rorer Sa | Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent |
TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
TW349948B (en) | 1995-10-31 | 1999-01-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 2-quinolone derivatives |
SI1162201T1 (sl) | 1995-12-08 | 2006-08-31 | Janssen Pharmaceutica Nv | (Imidazol-5-il)metil-2-kinolinonski derivati kot inhibitorji farnezil protein transferaze |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US5968965A (en) | 1996-01-30 | 1999-10-19 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
US5852010A (en) | 1996-04-03 | 1998-12-22 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5869682A (en) | 1996-04-03 | 1999-02-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5939557A (en) | 1996-04-03 | 1999-08-17 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5880140A (en) | 1996-04-03 | 1999-03-09 | Merck & Co., Inc. | Biheteroaryl inhibitors of farnesyl-protein transferase |
AU707139B2 (en) | 1996-04-03 | 1999-07-01 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5780492A (en) | 1996-04-03 | 1998-07-14 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5891889A (en) | 1996-04-03 | 1999-04-06 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US5965578A (en) | 1996-04-03 | 1999-10-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
CA2251716A1 (en) | 1996-04-15 | 1997-10-23 | W. Gillies Mckenna | Sensitization of cells to radiation and chemotherapy |
US5760395A (en) | 1996-04-18 | 1998-06-02 | Universities Research Assoc., Inc. | Method and apparatus for laser-controlled proton beam radiology |
US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
US5767274A (en) | 1996-06-28 | 1998-06-16 | Biomeasure, Incorporated | Prenyl transferase inhibitors |
US5773455A (en) | 1996-06-28 | 1998-06-30 | Biomeasure, Incorporated | Inhibitors of prenyl transferases |
US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
KR100232231B1 (ko) | 1996-09-13 | 2000-03-02 | 김영환 | 비휘발성 메모리 소자의 데이터 기입 장치 및 방법 |
CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
DE69730093T2 (de) | 1996-10-31 | 2006-07-20 | Takeda Pharmaceutical Co. Ltd. | Zubereitung mit verzögerter Freisetzung |
US5972966A (en) | 1996-12-05 | 1999-10-26 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
US6197350B1 (en) | 1996-12-20 | 2001-03-06 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
JP2001505548A (ja) | 1996-12-20 | 2001-04-24 | トヴァリシェストヴォ エス オグラニチェンノイ オトヴェトストヴェンノストジュ“タブジュファーム” | 凍結乾燥ハイドロクロライド−1β,10β−エポキシ−13−ジメチルアミノ−グアヤ−3(4)−エン−6,12−オリドの生成方法および装置 |
US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
TW591030B (en) | 1997-03-10 | 2004-06-11 | Janssen Pharmaceutica Nv | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles |
CA2288140C (en) | 1997-04-25 | 2007-04-03 | Janssen Pharmaceutica N.V. | Farnesyltransferase inhibiting quinazolinones |
JP4209472B2 (ja) | 1997-06-02 | 2009-01-14 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 平滑筋細胞増殖のインヒビターとしての(イミダゾール−5−イル)メチル−2−キノリノン誘導体 |
TR200002059T2 (tr) | 1998-01-16 | 2001-01-22 | Takeda Chemical Industries, Ltd. | Devamlı salınan bileşim, üretim yöntemi ve kullanımı. |
ATE220278T1 (de) | 1998-03-05 | 2002-07-15 | Formula One Administration Ltd | Datenübertragungssystem |
US6303654B1 (en) | 1998-03-12 | 2001-10-16 | Wisconsin Alumni Research Foundation | Acyclic monoterpenoid derivatives |
US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
WO2000001691A1 (en) | 1998-07-01 | 2000-01-13 | Merck & Co., Inc. | Process for making farnesyl-protein transferase inhibitors |
BR9911869A (pt) | 1998-07-06 | 2001-03-27 | Janssen Pharmaceutica Nv | Inibidores da transferase da proteìna farnesil para o tratamento das artropatias |
CA2336624C (en) | 1998-07-06 | 2008-10-21 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors with in vivo radiosensitizing properties |
JP3495706B2 (ja) | 1998-08-27 | 2004-02-09 | ファイザー・プロダクツ・インク | 抗癌薬として有用なアルキニル置換キノリン−2−オン誘導体 |
ES2237125T3 (es) | 1998-08-27 | 2005-07-16 | Pfizer Products Inc. | Derivados de quinolin-2-ona utiles como agentes anticancerigenos. |
US6927024B2 (en) | 1998-11-30 | 2005-08-09 | Genentech, Inc. | PCR assay |
IL143859A0 (en) | 1998-12-23 | 2002-04-21 | Janssen Pharmaceutica Nv | 1,2-annelated quinoline derivatives |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US20040157882A1 (en) | 1999-11-30 | 2004-08-12 | End David William | Method of use of (imidazol-5-yl)methyl-2-quinolinone derivatives to inhibit smooth muscle cell proliferation |
US7186507B2 (en) | 1999-12-09 | 2007-03-06 | Indiana University Research And Technology Corporation | Fluorescent in situ RT-PCR |
EP1255537B1 (en) | 2000-02-04 | 2006-04-19 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for treating breast cancer |
WO2001062234A2 (en) | 2000-02-24 | 2001-08-30 | Janssen Pharmaceutica N.V. | Dosing regimen |
JO2361B1 (en) | 2000-06-22 | 2006-12-12 | جانسين فارماسيوتيكا ان. في | Enaniumer 1,2-anylated quinoline inhibitor for the transporter - farnesyl |
PT1339407E (pt) | 2000-11-28 | 2006-08-31 | Janssen Pharmaceutica Nv | Inibidores da proteina farnesil transferase para o tratamento de doenca inflamatoria do intestino |
US20040110769A1 (en) | 2001-02-15 | 2004-06-10 | End David William | Farnesyl protein transferase inhibitor combinations with antiestrogen agents |
US7101663B2 (en) | 2001-03-02 | 2006-09-05 | University of Pittsburgh—of the Commonwealth System of Higher Education | PCR method |
JP4257698B2 (ja) | 2001-03-12 | 2009-04-22 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | イミダゾール化合物の製造方法 |
WO2002085364A1 (en) | 2001-04-25 | 2002-10-31 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitors for treating cachexia |
DE60222590T2 (de) | 2001-10-30 | 2008-06-19 | Ortho-Clinical Diagnostics, Inc. | Methoden zur feststellung von akute myeloischen leukämie |
AU2003223970B2 (en) | 2002-03-22 | 2008-03-06 | Janssen Pharmaceutica N.V. | Benzylimidazolyl substituted 2-quinoline and quinazoline derivatives for use as farnesyl transferase inhibitors |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7122799B2 (en) | 2003-12-18 | 2006-10-17 | Palo Alto Research Center Incorporated | LED or laser enabled real-time PCR system and spectrophotometer |
US7524961B2 (en) | 2004-05-03 | 2009-04-28 | Janssen Pharmaceutica, N.V. | Diastereoselective addition of lithiated N-methylimidazole on sulfinimines |
ATE397600T1 (de) | 2004-05-03 | 2008-06-15 | Janssen Pharmaceutica Nv | Diastereoselektives syntheseverfahren zur herstellung vn imidazolverbindungen |
JP4917022B2 (ja) | 2004-05-03 | 2012-04-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 6−ブロモ−4−(3−クロロフェニル)−2−メトキシ−キノリンを用いるジアステレオ選択的合成方法 |
PT1815247E (pt) | 2004-11-05 | 2013-04-23 | Janssen Pharmaceutica Nv | Uso terapêutico de inibidores de farnesiltransferase e métodos para monitorizar a eficácia do mesmo |
AU2006341131A1 (en) | 2005-10-14 | 2007-10-04 | Janssen Pharmaceutica, N.V. | Formulations of tipifarnib for intravenous administration |
US7932036B1 (en) | 2008-03-12 | 2011-04-26 | Veridex, Llc | Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase |
KR20110015448A (ko) | 2008-06-03 | 2011-02-15 | 얀센 파마슈티카 엔.브이. | 암 치료와 관련된 혈액 질환을 예방하기 위한 tpo 모방 펩티드 |
AU2011282614B2 (en) | 2010-07-28 | 2015-11-26 | Janssen Pharmaceutica Nv | Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors |
US11559540B2 (en) | 2010-07-28 | 2023-01-24 | Janssen Pharmaceutica Nv | Method of determining acute myeloid leukemia response to treatment with farnesyltransferase inhibitors |
HUE044238T2 (hu) | 2013-03-13 | 2019-10-28 | Oncoceutics Inc | 7-benzil-10-(2-metilbenzil)-2,6,7,8,9,10-hexahidroimidazo[l,2-a]pirido[4,3-d]pirimidin-5(3h)-on rák kezelésénél történõ alkalmazásra |
CA2946759A1 (en) * | 2014-04-25 | 2015-10-29 | Memorial Sloan-Kettering Cancer Center | Treatment of h-ras-driven tumors |
PT3277842T (pt) | 2015-08-17 | 2019-09-05 | Kura Oncology Inc | Métodos de tratamento de doentes com cancro usando inibidores da farnesiltransferase |
EP3838275A1 (en) | 2016-11-03 | 2021-06-23 | Kura Oncology, Inc. | Farnesyltransferase inhibitors for use in methods of treating cancer |
-
2017
- 2017-11-02 EP EP20212873.2A patent/EP3838275A1/en not_active Withdrawn
- 2017-11-02 PT PT178424289T patent/PT3534885T/pt unknown
- 2017-11-02 EP EP17842428.9A patent/EP3534885B1/en active Active
- 2017-11-02 AU AU2017353838A patent/AU2017353838A1/en not_active Abandoned
- 2017-11-02 JP JP2019522914A patent/JP2019534290A/ja active Pending
- 2017-11-02 DK DK17842428.9T patent/DK3534885T3/da active
- 2017-11-02 LT LTEP17842428.9T patent/LT3534885T/lt unknown
- 2017-11-02 ES ES17842428T patent/ES2863730T3/es active Active
- 2017-11-02 HU HUE17842428A patent/HUE053927T2/hu unknown
- 2017-11-02 BR BR112019009000A patent/BR112019009000A2/pt not_active IP Right Cessation
- 2017-11-02 CN CN201780081965.XA patent/CN110325212B/zh active Active
- 2017-11-02 MX MX2019005065A patent/MX2019005065A/es unknown
- 2017-11-02 KR KR1020197015025A patent/KR20190082247A/ko active Search and Examination
- 2017-11-02 RS RS20210406A patent/RS61745B1/sr unknown
- 2017-11-02 CA CA3042747A patent/CA3042747A1/en not_active Abandoned
- 2017-11-02 SG SG11201903786UA patent/SG11201903786UA/en unknown
- 2017-11-02 MY MYPI2019002264A patent/MY190861A/en unknown
- 2017-11-02 PL PL17842428T patent/PL3534885T3/pl unknown
- 2017-11-02 US US15/802,233 patent/US11124839B2/en active Active
- 2017-11-02 EA EA201991091A patent/EA201991091A1/ru unknown
- 2017-11-02 SI SI201730693T patent/SI3534885T1/sl unknown
- 2017-11-02 TW TW106137968A patent/TW201818965A/zh unknown
- 2017-11-02 WO PCT/US2017/059686 patent/WO2018085518A2/en unknown
- 2017-11-02 AR ARP170103042A patent/AR110031A1/es unknown
-
2019
- 2019-04-22 IL IL266182A patent/IL266182A/en unknown
- 2019-04-25 PH PH12019500927A patent/PH12019500927A1/en unknown
-
2021
- 2021-04-06 HR HRP20210544TT patent/HRP20210544T1/hr unknown
- 2021-08-17 US US17/404,854 patent/US20210381063A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
PL3534885T3 (pl) | 2021-11-15 |
WO2018085518A2 (en) | 2018-05-11 |
EP3838275A1 (en) | 2021-06-23 |
IL266182A (en) | 2019-06-30 |
EP3534885A2 (en) | 2019-09-11 |
HUE053927T2 (hu) | 2021-07-28 |
EA201991091A1 (ru) | 2019-11-29 |
KR20190082247A (ko) | 2019-07-09 |
EP3534885B1 (en) | 2021-01-20 |
MY190861A (en) | 2022-05-12 |
US20180187266A1 (en) | 2018-07-05 |
SI3534885T1 (sl) | 2021-08-31 |
AU2017353838A1 (en) | 2019-05-23 |
DK3534885T3 (da) | 2021-04-12 |
PT3534885T (pt) | 2021-04-13 |
TW201818965A (zh) | 2018-06-01 |
ES2863730T3 (es) | 2021-10-11 |
CA3042747A1 (en) | 2018-05-11 |
JP2019534290A (ja) | 2019-11-28 |
CN110325212A (zh) | 2019-10-11 |
US20210381063A1 (en) | 2021-12-09 |
CN110325212B (zh) | 2022-03-22 |
BR112019009000A2 (pt) | 2019-07-16 |
US11124839B2 (en) | 2021-09-21 |
AR110031A1 (es) | 2019-02-13 |
MX2019005065A (es) | 2019-08-21 |
RS61745B1 (sr) | 2021-05-31 |
WO2018085518A3 (en) | 2018-07-12 |
SG11201903786UA (en) | 2019-05-30 |
PH12019500927A1 (en) | 2019-08-19 |
LT3534885T (lt) | 2021-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20210544T1 (hr) | Inhibitori farneziltransferaze za uporabu u liječenju raka | |
BR112016028641A2 (pt) | ?método para tratar câncer? | |
BR112015024621A2 (pt) | c. novyi para o tratamento de tumores sólidos em seres humanos | |
MX2021010145A (es) | Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb. | |
PH12020552274A1 (en) | Formulations of an axl/mer inhibitor | |
MX2021004207A (es) | Uso de reboxetina para el tratamiento de narcolepsia. | |
MX2022002312A (es) | Composicion farmaceutica para tratar cancer utilizada para un paciente que tiene un marcador genetico especifico. | |
GB2571668A (en) | Stem cell conditioned media for clinical and cosmetic applications | |
JP2015044878A5 (hr) | ||
MX2021011529A (es) | Chiauranib para el tratamiento de cáncer de pulmón microcítico. | |
WO2018085516A3 (en) | Non-mesenchymal human lung stem cells and methods of their use for treating respiratory diseases | |
PH12017500754A1 (en) | Cancer and skin lesion treatment | |
MY194694A (en) | Method and composition for treating cancer or skin lesion using a vaccine | |
CN107468691A (zh) | 阿西替尼在治疗鼻咽癌方面的应用 | |
CN104873742A (zh) | 一种治疗胸腔积液的中药组合物 | |
BR112022019334A2 (pt) | Método para produzir um genoma viral interferente defeituoso, genomas virais interferentes defeituosos, partícula interferente defeituosa, método de tratamento de uma infecção viral, genoma interferente defeituoso, composição farmacêutica, imunogênica ou terapêutica, vacina, uso, polinucleotídeo, vetor de expressão ou plasmídeo e linhagem de células | |
Hwang et al. | Mandibular Reconstruction using Simulation Surgery after Segmental Mandibulectomy | |
ZA202200330B (en) | Pharmaceutical composition of imatinib | |
MX2021013594A (es) | Derivados de amida utiles en el tratamiento de la infeccion por vhb o de enfermedades inducidas por vhb. | |
CN104922583A (zh) | 一种专治胆结石的中药 | |
CN104491248A (zh) | 一种治疗原发性血小板增多症的药物及其制备方法 | |
CR20220247A (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
Koval et al. | INVOLVEMENT OF VARIOUS CELL DEATH MODALITIES IN CYTOTOXIC ACTIVITY OF LACTAPTIN ANALOG | |
CN105616802A (zh) | 治脾虚湿困证飞蚊症的中药配方 | |
Tuluc et al. | P53 Expression in Oropharyngeal Squamous Cell Carcinoma in Increased in HPV Positive Smokers |